616 related articles for article (PubMed ID: 31651562)
1. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
[TBL] [Abstract][Full Text] [Related]
2. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
Andraka-Christou B; Atkins D
Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
[TBL] [Abstract][Full Text] [Related]
3. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
[No Abstract] [Full Text] [Related]
4. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
Bello JK; Xu KY; Salas J; Bedrick BS; Grucza RA
J Gen Intern Med; 2024 Jun; 39(8):1342-1348. PubMed ID: 38424347
[TBL] [Abstract][Full Text] [Related]
7. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
[TBL] [Abstract][Full Text] [Related]
8. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.
Jaffe K; Slat S; Chen L; Macleod C; Bohnert A; Lagisetty P
J Subst Use Addict Treat; 2024 Aug; 163():209361. PubMed ID: 38703949
[TBL] [Abstract][Full Text] [Related]
9. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
[TBL] [Abstract][Full Text] [Related]
10. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.
Morgan JR; Walley AY; Murphy SM; Chatterjee A; Hadland SE; Barocas J; Linas BP; Assoumou SA
Drug Alcohol Depend; 2021 Aug; 225():108764. PubMed ID: 34051547
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.
Cioe K; Biondi BE; Easly R; Simard A; Zheng X; Springer SA
J Subst Abuse Treat; 2020 Dec; 119():108146. PubMed ID: 33138929
[TBL] [Abstract][Full Text] [Related]
12. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
[TBL] [Abstract][Full Text] [Related]
13. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
[No Abstract] [Full Text] [Related]
14. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.
Saunders EC; Moore SK; Walsh O; Metcalf SA; Budney AJ; Scherer E; Marsch LA
J Subst Abuse Treat; 2020 Apr; 111():54-66. PubMed ID: 32076361
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
[TBL] [Abstract][Full Text] [Related]
16. Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
Booty MD; Harp K; Batty E; Knudsen HK; Staton M; Oser CB
J Subst Use Addict Treat; 2023 Jun; 149():209051. PubMed ID: 37084815
[TBL] [Abstract][Full Text] [Related]
17. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
[TBL] [Abstract][Full Text] [Related]
18. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV.
Fanucchi L; Springer SA; Korthuis PT
Curr HIV/AIDS Rep; 2019 Feb; 16(1):1-6. PubMed ID: 30684117
[TBL] [Abstract][Full Text] [Related]
19. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
20. Attitudes toward and training in medications for opioid use disorders: a descriptive analysis among employees in the youth legal system and community mental health centers.
O'Reilly LM; Schwartz K; Brown SA; Dir A; Gillenwater L; Adams Z; Zapolski T; Hulvershorn LA; Aalsma M
Subst Abuse Treat Prev Policy; 2024 Jun; 19(1):32. PubMed ID: 38907286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
